Publications
192
Citations
14,373
Est. group size
—
Recurring co-author estimate
Active years
61
Publishing since 1966
Magdalena Korecka's research focuses on developing and validating laboratory methods to detect and measure biomarkers of Alzheimer's disease, such as amyloid-beta and tau proteins, in blood plasma and cerebrospinal fluid. A major thread is moving from invasive spinal-fluid tests toward reliable blood-based tests using techniques like mass spectrometry. Much of this work supports large multi-site studies and clinical trials, including efforts to compare biomarker performance across different racial groups and to monitor patients' responses to anti-amyloid therapies.
Publication activity has been steady over the past decade, averaging roughly seven to eight papers per year with a notable peak in 2020 and continued strong output in 2025.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Analysis of second-generation epigenetic clocks reveals further associations between disproportionate biological ageing and hippocampal volume
GeroScience · 2026
- Comparison of plasma p‐tau217/Aβ42, p‐tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease
Alzheimer s & Dementia · 2025
- Tau-Clinical Mismatch Identifies Individuals with Co-Pathology and Predicts Clinical Trajectory
medRxiv · 2025
- Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer’s Disease using PET and Plasma Biomarkers
medRxiv · 2025
- Personalized Monitoring of Response to Anti‐Amyloid Therapy in a Real‐World Cohort using Clinical Assessment and Plasma Biomarkers
Alzheimer s & Dementia · 2025
- Tau Cognitive Mismatch in Alzheimer's Disease Predicts Presence of Co‐Pathology and Diverging Disease Trajectory
Alzheimer s & Dementia · 2025
- Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch
JAMA Neurology · 2025
- Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease
JAMA Neurology · 2025
- ADNI Biomarker Core: A review of progress since 2004 and future challenges
Alzheimer s & Dementia · 2024
- Comparison of plasma p‐tau<sub>217</sub> and Aβ<sub>42</sub>/Aβ<sub>40</sub> biomarkers by race to detect Alzheimer’s disease
Alzheimer s & Dementia · 2024
- The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research
Alzheimer s & Dementia · 2024
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
Clinical Chemistry · 2023
- Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
Neurology · 2021
- Mass spectrometry‐based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids
Journal of Neurochemistry · 2021
- The global Alzheimer's Association round robin study on plasma amyloid β methods
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2021
- Scientific Reports×17
- Alzheimer s & Dementia×17
- Nature Communications×14
- Neurology×12
- GeroScience×8
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile